Differential expression of PD-L1 and PD-L2, ligands for an inhibitory receptor PD-1, in the cells of lymphohematopoietic tissues - PubMed (original) (raw)
Differential expression of PD-L1 and PD-L2, ligands for an inhibitory receptor PD-1, in the cells of lymphohematopoietic tissues
Masayoshi Ishida et al. Immunol Lett. 2002.
Abstract
PD-1 is a member of the immunoglobulin superfamily expressed on immune cells, including T and B cells, and is involved in the delivery of inhibitory signal upon engagement of its ligands, PD-L1 and PD-L2. While the expression profile of PD-1 has been well documented, the analysis of PD-L1 and PD-L2 distributions on a protein basis has not been carried out because of the lack of available monoclonal antibodies specific for the molecules. In this study, we established two monoclonal antibodies, 1-111A and 122, specific for murine PD-L1 and PD-L2, respectively, and examined their expression profiles. Based on flow cytometric analyses, the expression of PD-L1 was detected in a variety of lymphohematopoietic cell types, including a minor proportion of T and B cells in the spleen, majority of pre-B cells and myeloid cells in bone marrow and subsets of thymocytes, while the expression of PD-L2 was not observed in the lymphohematopoietic cells at all. Notably, a significant proportion of the most immature lineage-marker-negative and c-Kit-positive bone marrow cells containing stem cells did express PD-L1. Following mitogenic stimulation, essentially all lymphocytes expressed PD-L1. Furthermore, a variety of leukemic lines also expressed PD-L1, while none of them did PD-L2. Thus, present results demonstrate the distinct expression patterns of PD-L1 and PD-L2 with the cells of lymphohematopoietic tissues exclusively expressing the former.
Similar articles
- Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production.
Brown JA, Dorfman DM, Ma FR, Sullivan EL, Munoz O, Wood CR, Greenfield EA, Freeman GJ. Brown JA, et al. J Immunol. 2003 Feb 1;170(3):1257-66. doi: 10.4049/jimmunol.170.3.1257. J Immunol. 2003. PMID: 12538684 - Expression of programmed death 1 ligands by murine T cells and APC.
Yamazaki T, Akiba H, Iwai H, Matsuda H, Aoki M, Tanno Y, Shin T, Tsuchiya H, Pardoll DM, Okumura K, Azuma M, Yagita H. Yamazaki T, et al. J Immunol. 2002 Nov 15;169(10):5538-45. doi: 10.4049/jimmunol.169.10.5538. J Immunol. 2002. PMID: 12421930 - Blocking programmed death-1 ligand-PD-1 interactions by local gene therapy results in enhancement of antitumor effect of secondary lymphoid tissue chemokine.
He YF, Zhang GM, Wang XH, Zhang H, Yuan Y, Li D, Feng ZH. He YF, et al. J Immunol. 2004 Oct 15;173(8):4919-28. doi: 10.4049/jimmunol.173.8.4919. J Immunol. 2004. PMID: 15470033 - Negative regulation of T-cell function by PD-1.
Zha Yy, Blank C, Gajewski TF. Zha Yy, et al. Crit Rev Immunol. 2004;24(4):229-37. doi: 10.1615/critrevimmunol.v24.i4.10. Crit Rev Immunol. 2004. PMID: 15588223 Review. - Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: implications for tumor immunotherapy.
Blank C, Gajewski TF, Mackensen A. Blank C, et al. Cancer Immunol Immunother. 2005 Apr;54(4):307-14. doi: 10.1007/s00262-004-0593-x. Epub 2004 Dec 15. Cancer Immunol Immunother. 2005. PMID: 15599732 Free PMC article. Review.
Cited by
- Toxicity in the era of immune checkpoint inhibitor therapy.
Keam S, Turner N, Kugeratski FG, Rico R, Colunga-Minutti J, Poojary R, Alekseev S, Patel AB, Li YJ, Sheshadri A, Loghin ME, Woodman K, Aaroe AE, Hamidi S, Iyer PC, Palaskas NL, Wang Y, Nurieva R. Keam S, et al. Front Immunol. 2024 Aug 23;15:1447021. doi: 10.3389/fimmu.2024.1447021. eCollection 2024. Front Immunol. 2024. PMID: 39247203 Free PMC article. Review. - Exploring the Role of PD-1 in the Autoimmune Response: Insights into Its Implication in Systemic Lupus Erythematosus.
Sagrero-Fabela N, Chávez-Mireles R, Salazar-Camarena DC, Palafox-Sánchez CA. Sagrero-Fabela N, et al. Int J Mol Sci. 2024 Jul 15;25(14):7726. doi: 10.3390/ijms25147726. Int J Mol Sci. 2024. PMID: 39062968 Free PMC article. Review. - PD-1 Limits IL-2 Production and Thymic Regulatory T Cell Development.
Caruso B, Weeder BR, Thompson RF, Moran AE. Caruso B, et al. Immunohorizons. 2024 Mar 1;8(3):281-294. doi: 10.4049/immunohorizons.2300079. Immunohorizons. 2024. PMID: 38551395 Free PMC article. - Multiple influence of immune cells in the bone metastatic cancer microenvironment on tumors.
Chen S, Lei J, Mou H, Zhang W, Jin L, Lu S, Yinwang E, Xue Y, Shao Z, Chen T, Wang F, Zhao S, Chai X, Wang Z, Zhang J, Zhang Z, Ye Z, Li B. Chen S, et al. Front Immunol. 2024 Feb 23;15:1335366. doi: 10.3389/fimmu.2024.1335366. eCollection 2024. Front Immunol. 2024. PMID: 38464516 Free PMC article. Review. - Immune checkpoint inhibitors in bone metastasis: Clinical challenges, toxicities, and mechanisms.
Joseph GJ, Johnson DB, Johnson RW. Joseph GJ, et al. J Bone Oncol. 2023 Sep 30;43:100505. doi: 10.1016/j.jbo.2023.100505. eCollection 2023 Dec. J Bone Oncol. 2023. PMID: 37842554 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Research Materials
Miscellaneous